Literature DB >> 19902521

The role of interferons in the treatment of osteosarcoma.

Jeremy Whelan1, Daniel Patterson, Martha Perisoglou, Stefan Bielack, Neyssa Marina, Sigbjorn Smeland, Mark Bernstein.   

Abstract

Interferons, a group of cytokines with antiangiogenic, direct antitumour and immunostimulating properties, have shown significant activity against osteosarcoma in vitro and in xenograft models. They have also been used in osteosarcoma clinical trials as a single adjuvant to surgery, with an apparent increase in relapse-free survival. In the ongoing EURAMOS 1 clinical trial, interferon alpha-2b is evaluated as an adjuvant treatment in osteosarcoma. This article reviews the rationale for the use of interferon in cancer with special reference to the treatment of osteosarcoma, including all published data of clinical efficacy in this disease. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19902521     DOI: 10.1002/pbc.22136

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  23 in total

1.  Ubiquitination-dependent regulation of signaling receptors in cancer.

Authors:  Wei-Chun Huangfu; Serge Y Fuchs
Journal:  Genes Cancer       Date:  2010-07

2.  Visfatin is involved in the cisplatin resistance of osteosarcoma cells via upregulation of Snail and Zeb1.

Authors:  Dexing Wang; Guowei Qian; Jin Wang; Tian Wang; Lian Zhang; Ping Yang; Feng Lin
Journal:  Cancer Biol Ther       Date:  2019-04-12       Impact factor: 4.742

Review 3.  Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.

Authors:  Douglas J Harrison; Cindy L Schwartz
Journal:  Curr Treat Options Oncol       Date:  2017-04

Review 4.  Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.

Authors:  Ingrid Lilienthal; Nikolas Herold
Journal:  Int J Mol Sci       Date:  2020-09-19       Impact factor: 5.923

5.  Strategies and developments of immunotherapies in osteosarcoma.

Authors:  Jia Wan; Xianghong Zhang; Tang Liu; Xiangsheng Zhang
Journal:  Oncol Lett       Date:  2015-11-24       Impact factor: 2.967

6.  Regulation of interferon pathway in 2-methoxyestradiol-treated osteosarcoma cells.

Authors:  Fritz Wimbauer; Caihong Yang; Kristen L Shogren; Minzhi Zhang; Ribu Goyal; Scott M Riester; Michael J Yaszemski; Avudaiappan Maran
Journal:  BMC Cancer       Date:  2012-03-19       Impact factor: 4.430

Review 7.  Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature.

Authors:  J PosthumaDeBoer; M A Witlox; G J L Kaspers; B J van Royen
Journal:  Clin Exp Metastasis       Date:  2011-04-02       Impact factor: 5.150

8.  Bone sarcomas: from biology to targeted therapies.

Authors:  Nathalie Gaspar; Angela Di Giannatale; Birgit Geoerger; Françoise Redini; Nadège Corradini; Natacha Enz-Werle; Franck Tirode; Perrine Marec-Berard; Jean-Claude Gentet; Valérie Laurence; Sophie Piperno-Neumann; Odile Oberlin; Laurence Brugieres
Journal:  Sarcoma       Date:  2012-11-27

9.  Current therapeutic strategies and novel approaches in osteosarcoma.

Authors:  Kosei Ando; Marie-Françoise Heymann; Verena Stresing; Kanji Mori; Françoise Rédini; Dominique Heymann
Journal:  Cancers (Basel)       Date:  2013-05-24       Impact factor: 6.639

10.  Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis.

Authors:  Dagmar Berghuis; Marco W Schilham; Hanneke I Vos; Susy J Santos; Stephan Kloess; Emilie P Buddingh'; R Maarten Egeler; Pancras Cw Hogendoorn; Arjan C Lankester
Journal:  Clin Sarcoma Res       Date:  2012-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.